# Standard Biotools Inc.: financial statements, quarterly

LAB · Nasdaq · CIK 1162194 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lab.md) · [Financials](/companies/lab/financials.md) · [Filings](/companies/lab/filings.md) · [Insiders](/companies/lab/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lab/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [25.4](/filings/0000950170-24-122473.md) | [28.2 d](/filings/0001193125-26-108326.md) | [45.5](/filings/0000950170-25-064606.md) | [22.5](/filings/0000950170-25-109388.md) | [22.1](/filings/0001193125-25-264695.md) | [24.8 d](/filings/0001193125-26-108326.md) | [20.2](/filings/0001193125-26-208967.md) | [21.8](/filings/0001193125-26-335103.md) | [19.6](/filings/0001193125-25-264695.md) | [23.8 d](/filings/0001193125-26-108326.md) | [21.1](/filings/0001193125-26-208967.md) | [20.1](/filings/0001193125-26-335103.md) |
| Cost of revenue | $m | [14.2](/filings/0000950170-24-122473.md) | [14.8 d](/filings/0001193125-26-108326.md) | [21.4](/filings/0000950170-25-064606.md) | [12.1](/filings/0000950170-25-109388.md) | [10.0](/filings/0001193125-25-264695.md) | [13.4 d](/filings/0001193125-26-108326.md) | [9.2](/filings/0001193125-26-208967.md) | [11.1](/filings/0001193125-26-335103.md) | [10.1](/filings/0001193125-25-264695.md) | [12.4 d](/filings/0001193125-26-108326.md) | [9.8](/filings/0001193125-26-208967.md) | [9.6](/filings/0001193125-26-335103.md) |
| Gross profit | $m | [11.2](/filings/0000950170-24-122473.md) | [13.4 d](/filings/0001193125-26-108326.md) | [24.2](/filings/0000950170-25-064606.md) | [10.4](/filings/0000950170-25-109388.md) | [12.1](/filings/0001193125-25-264695.md) | [11.4 d](/filings/0001193125-26-108326.md) | [11.0](/filings/0001193125-26-208967.md) | [10.6](/filings/0001193125-26-335103.md) | [9.5](/filings/0001193125-25-264695.md) | [11.4 d](/filings/0001193125-26-108326.md) | [11.3](/filings/0001193125-26-208967.md) | [10.5](/filings/0001193125-26-335103.md) |
| Research and development | $m | [6.4](/filings/0000950170-24-122473.md) | [6.9 d](/filings/0001193125-26-108326.md) | [16.0](/filings/0000950170-25-064606.md) | [7.2](/filings/0000950170-25-109388.md) | [6.9](/filings/0001193125-25-264695.md) | [7.0 d](/filings/0001193125-26-108326.md) | [5.4](/filings/0001193125-26-208967.md) | [6.2](/filings/0001193125-26-335103.md) | [6.4](/filings/0001193125-25-264695.md) | [8.0 d](/filings/0001193125-26-108326.md) | [2.1](/filings/0001193125-26-208967.md) | [2.0](/filings/0001193125-26-335103.md) |
| Selling, general and administrative | $m | [22.3](/filings/0000950170-24-122473.md) | [21.4 d](/filings/0001193125-26-108326.md) | [46.9](/filings/0000950170-25-064606.md) | [24.9](/filings/0000950170-25-109388.md) | [24.5](/filings/0001193125-25-264695.md) | [27.3 d](/filings/0001193125-26-108326.md) | [29.8](/filings/0001193125-26-208967.md) | [28.1](/filings/0001193125-26-335103.md) | [26.6](/filings/0001193125-25-264695.md) | [25.3 d](/filings/0001193125-26-108326.md) | [18.6](/filings/0001193125-26-208967.md) | [16.4](/filings/0001193125-26-335103.md) |
| Operating income | $m | [(21.2)](/filings/0000950170-24-122473.md) | [(21.4) d](/filings/0001193125-26-108326.md) | [(60.2)](/filings/0000950170-25-064606.md) | [(30.3)](/filings/0000950170-25-109388.md) | [(26.7)](/filings/0001193125-25-264695.md) | [(26.1) d](/filings/0001193125-26-108326.md) | [(27.0)](/filings/0001193125-26-208967.md) | [(25.7)](/filings/0001193125-26-335103.md) | [(32.9)](/filings/0001193125-25-264695.md) | [(24.6) d](/filings/0001193125-26-108326.md) | [(12.5)](/filings/0001193125-26-208967.md) | [(25.4)](/filings/0001193125-26-335103.md) |
| Interest expense | $m | [1.2](/filings/0000950170-23-060385.md) | [1.1 d](/filings/0000950170-24-023845.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.1](/filings/0000950170-24-122473.md) | [(0.2) d](/filings/0001193125-26-108326.md) | [0.1](/filings/0000950170-25-064606.md) | [0.0](/filings/0000950170-25-109388.md) | [0.1](/filings/0001193125-25-264695.md) | [0.3 d](/filings/0001193125-26-108326.md) | [(0.1)](/filings/0001193125-26-208967.md) | [(0.6)](/filings/0001193125-26-335103.md) | [(1.2)](/filings/0001193125-25-264695.md) | [(35.9) d](/filings/0001193125-26-108326.md) | [0.0](/filings/0001193125-26-208967.md) | [0.1](/filings/0001193125-26-335103.md) |
| Net income | $m | [(21.0)](/filings/0000950170-24-122473.md) | [(19.8) d](/filings/0001193125-26-108326.md) | [(32.2)](/filings/0001193125-25-264695.md) | [(45.7)](/filings/0001193125-25-264695.md) | [(26.9)](/filings/0001193125-25-264695.md) | [(34.1) d](/filings/0001193125-26-108326.md) | [(26.0)](/filings/0001193125-26-335103.md) | [(33.5)](/filings/0001193125-26-335103.md) | [(34.7)](/filings/0001193125-25-264695.md) | [19.3 d](/filings/0001193125-26-108326.md) | [127](/filings/0001193125-26-335103.md) | [(26.8)](/filings/0001193125-26-335103.md) |
| Diluted EPS | $ per share | [(0.27)](/filings/0000950170-24-122473.md) | not reported | [(0.27)](/filings/0000950170-25-064606.md) | [(0.12)](/filings/0000950170-25-109388.md) | [(0.07)](/filings/0001193125-25-264695.md) | not reported | [(0.07)](/filings/0001193125-26-208967.md) | [(0.09)](/filings/0001193125-26-335103.md) | [(0.09)](/filings/0001193125-25-264695.md) | not reported | [0.33](/filings/0001193125-26-208967.md) | [(0.07)](/filings/0001193125-26-335103.md) |
| Basic EPS | $ per share | [(0.27)](/filings/0000950170-24-122473.md) | not reported | [(0.27)](/filings/0000950170-25-064606.md) | [(0.12)](/filings/0000950170-25-109388.md) | [(0.07)](/filings/0001193125-25-264695.md) | not reported | [(0.07)](/filings/0001193125-26-208967.md) | [(0.09)](/filings/0001193125-26-335103.md) | [(0.09)](/filings/0001193125-25-264695.md) | not reported | [0.33](/filings/0001193125-26-208967.md) | [(0.07)](/filings/0001193125-26-335103.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [79.7](/filings/0000950170-23-060385.md) | [51.7](/filings/0000950170-25-036608.md) | [287](/filings/0000950170-24-057213.md) | [270](/filings/0000950170-24-091888.md) | [211](/filings/0000950170-24-122473.md) | [167](/filings/0001193125-26-108326.md) | [151](/filings/0000950170-25-064606.md) | [159](/filings/0000950170-25-109388.md) | [129](/filings/0001193125-25-264695.md) | [121](/filings/0001193125-26-335103.md) | [266](/filings/0001193125-26-208967.md) | [270](/filings/0001193125-26-335103.md) |
| Current assets | $m | [171](/filings/0000950170-23-060385.md) | [158](/filings/0000950170-25-036608.md) | [548](/filings/0000950170-24-057213.md) | [480](/filings/0000950170-24-091888.md) | [454](/filings/0000950170-24-122473.md) | [376](/filings/0001193125-26-108326.md) | [344](/filings/0000950170-25-064606.md) | [506](/filings/0000950170-25-109388.md) | [472](/filings/0001193125-25-264695.md) | [454](/filings/0001193125-26-335103.md) | [521](/filings/0001193125-26-208967.md) | [517](/filings/0001193125-26-335103.md) |
| Total assets | $m | [339](/filings/0000950170-23-060385.md) | [323](/filings/0000950170-25-036608.md) | [778](/filings/0000950170-24-057213.md) | [709](/filings/0000950170-24-091888.md) | [682](/filings/0000950170-24-122473.md) | [612](/filings/0001193125-26-108326.md) | [580](/filings/0000950170-25-064606.md) | [557](/filings/0000950170-25-109388.md) | [540](/filings/0001193125-25-264695.md) | [568](/filings/0001193125-26-335103.md) | [639](/filings/0001193125-26-208967.md) | [627](/filings/0001193125-26-335103.md) |
| Current liabilities | $m | [51.8](/filings/0000950170-23-060385.md) | [109](/filings/0000950170-25-036608.md) | [122](/filings/0000950170-24-057213.md) | [124](/filings/0000950170-24-091888.md) | [121](/filings/0000950170-24-122473.md) | [65.9](/filings/0001193125-26-108326.md) | [56.2](/filings/0000950170-25-064606.md) | [98.0](/filings/0000950170-25-109388.md) | [108](/filings/0001193125-25-264695.md) | [108](/filings/0001193125-26-335103.md) | [42.2](/filings/0001193125-26-208967.md) | [56.8](/filings/0001193125-26-335103.md) |
| Total liabilities | $m | [160](/filings/0000950170-23-060385.md) | [160](/filings/0000950170-25-036608.md) | [200](/filings/0000950170-24-057213.md) | [198](/filings/0000950170-24-091888.md) | [192](/filings/0000950170-24-122473.md) | [141](/filings/0001193125-26-108326.md) | [125](/filings/0000950170-25-064606.md) | [132](/filings/0000950170-25-109388.md) | [140](/filings/0001193125-25-264695.md) | [143](/filings/0001193125-26-335103.md) | [78.0](/filings/0001193125-26-208967.md) | [87.2](/filings/0001193125-26-335103.md) |
| Long-term debt | $m | [64.6](/filings/0000950170-23-060385.md) | [63.5](/filings/0000950170-25-036608.md) | [55.0](/filings/0000950170-24-057213.md) | [55.1](/filings/0000950170-24-091888.md) | [55.2](/filings/0000950170-24-122473.md) | [0.3](/filings/0000950170-25-036608.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(132)](/filings/0000950170-24-122473.md) | [(148)](/filings/0001193125-26-108326.md) | [577](/filings/0001193125-25-264695.md) | [510](/filings/0001193125-25-264695.md) | [489](/filings/0001193125-25-264695.md) | [472](/filings/0001193125-26-335103.md) | [455](/filings/0001193125-26-335103.md) | [425](/filings/0001193125-26-335103.md) | [400](/filings/0001193125-25-264695.md) | [424](/filings/0001193125-26-335103.md) | [561](/filings/0001193125-26-335103.md) | [540](/filings/0001193125-26-335103.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.4) d](/filings/0000950170-24-122473.md) | [(14.1) d](/filings/0001193125-26-108326.md) | [(62.5)](/filings/0000950170-25-064606.md) | [(39.1) d](/filings/0000950170-25-109388.md) | [(27.9) d](/filings/0001193125-25-264695.md) | [(14.1) d](/filings/0001193125-26-108326.md) | [(30.3)](/filings/0001193125-26-208967.md) | [(20.7) d](/filings/0001193125-26-335103.md) | [(22.2) d](/filings/0001193125-25-264695.md) | [(1.2) d](/filings/0001193125-26-108326.md) | [(46.6)](/filings/0001193125-26-208967.md) | [(10.3) d](/filings/0001193125-26-335103.md) |
| Capital expenditure | $m | [0.9 d](/filings/0000950170-24-122473.md) | [0.1 d](/filings/0001193125-26-108326.md) | [0.8](/filings/0000950170-25-064606.md) | [1.9 d](/filings/0000950170-25-109388.md) | [2.3 d](/filings/0001193125-25-264695.md) | [3.4 d](/filings/0001193125-26-108326.md) | [5.1](/filings/0001193125-26-208967.md) | [1.9 d](/filings/0001193125-26-335103.md) | [0.9 d](/filings/0001193125-25-264695.md) | [0.5 d](/filings/0001193125-26-108326.md) | [0.6](/filings/0001193125-26-208967.md) | [0.3 d](/filings/0001193125-26-335103.md) |
| Share repurchases | $m | [0.4](/filings/0000950170-23-060385.md) | [0.2 d](/filings/0001193125-26-108326.md) | [11.1](/filings/0000950170-25-064606.md) | [29.4 d](/filings/0000950170-25-109388.md) | [0.0 d](/filings/0001193125-25-264695.md) | [0.0 d](/filings/0001193125-26-108326.md) | [0.0](/filings/0000950170-25-064606.md) | [0.0 d](/filings/0000950170-25-109388.md) | [0.0 d](/filings/0001193125-25-264695.md) | [0.0 d](/filings/0001193125-26-108326.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q3 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [78.9](/filings/0000950170-23-060385.md) | [79.1](/filings/0000950170-24-057213.md) | [78.7](/filings/0000950170-24-091888.md) | [79.2](/filings/0000950170-24-122473.md) | [294](/filings/0000950170-25-064606.md) | [372](/filings/0000950170-25-109388.md) | [372](/filings/0001193125-25-264695.md) | [378](/filings/0001193125-26-208967.md) | [380](/filings/0001193125-26-335103.md) | [383](/filings/0001193125-25-264695.md) | [388](/filings/0001193125-26-208967.md) | [391](/filings/0001193125-26-335103.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 392,578,808 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335103.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.